# MAP: a Flowable, Precision-Engineered, and Tunable Tissue Scaffold Leveraging Hyper-Porous Geometry to Control Inflammation and Promote Regenerative Healing in Diabetic Wounds

> **NIH NIH R44** · TEMPO THERAPEUTICS, INC. · 2020 · $836,914

## Abstract

SUMMARY / ABSTRACT
Chronic diabetic foot ulcers (DFUs) are a significant worldwide healthcare burden, reaching a cost of $11
billion in the US alone during 2014. The current treatment capability is limited by (i) inability of standard wet-to-
dry bandaging techniques to heal these wounds and (ii) the high costs of advanced treatments such as tissue-
based or living-cell bioengineered skin substitutes. The high costs of these treatments have limited
reimbursement until after a wound is chronic. Each year in the US, ~1.5 million new and continuing DFU cases
are documented. Over their lifetime, a diabetic patient with a foot wound has a 20% chance of lower limb
amputation in the US. Reported mortality rates for DFU patients range from 55 to 74% after 5 years, which are
above cancers such as prostate, breast, and colon.
This significant clinical need and lack of cost-effective products creates significant market opportunity that can
be addressed with a biomaterial therapy with the efficacy of an advanced skin substitute at the cost of a wound
dressing. Low product cost and ease-of-use will drive reimbursement and adoption in the early (acute) phase
of wound care in these at-risk diabetic patients. The ability to control inflammation and promote tissue ingrowth
could mitigate the chronic wound phase, improving outcomes for patients and reducing costs to payers. Until
now, there have been no low-cost treatments that when applied can integrate into the wound bed and promote
regeneration without cells or biologics.
To answer this market need, Tempo Therapeutics is developing a suite of tissue regeneration biomaterials
based on our proprietary Microporous Annealed Particle (MAP) technology. MAP allows us to empower
synthetic chemical formulations with unique geometric scaffold structure. Our MAP materials are flowable
(ease of application) and fill wounds of multiple shapes and sizes and convert to a hyper-porous sponge-like
network in the wound site after exposure to LED white light. The hyper-porosity geometry promotes fast tissue
ingrowth, early vascularization, and faster wound re-epithelialization when compared to leading decellularized
tissue-based matrices, with minimal inflammatory response.
Tempo has developed our first product, the MAP Wound Matrix, for treatment of acute healthy wounds and has
recently submitted a regulatory application via direct De Novo to FDA with safety and performance data.
Tempo has completed initial scale-up of product manufacturing and is preparing for post market clinical data
efforts beginning in 2019.
In the proposed direct-to-phase II work, we will develop our second product based on the MAP technology,
targeting impaired healing in diabetic wounds. We will employ specialized models of impaired wound healing in
diabetic pigs, performed under Good Laboratory Practices (GLP), to test a suite of three formulation variants
already demonstrated in a preliminary healthy swine study. The optimal formulation of MAP that per...

## Key facts

- **NIH application ID:** 10015273
- **Project number:** 5R44DK124085-02
- **Recipient organization:** TEMPO THERAPEUTICS, INC.
- **Principal Investigator:** Stephanie Deshayes
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $836,914
- **Award type:** 5
- **Project period:** 2019-09-15 → 2021-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10015273

## Citation

> US National Institutes of Health, RePORTER application 10015273, MAP: a Flowable, Precision-Engineered, and Tunable Tissue Scaffold Leveraging Hyper-Porous Geometry to Control Inflammation and Promote Regenerative Healing in Diabetic Wounds (5R44DK124085-02). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10015273. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
